Pine River Capital Management’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Pine River Capital Management’s Portfolio TLOG Stock Details TLOG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-209,900	Closed	-$873K	–	1070
2014 Q3	$873K	Hold	209,900	–	–	0.01%	661
2014 Q2	$1.24M	Buy	209,900 +43,100	+26%	+$245K	0.02%	493
2014 Q1	$1.06M	Sell	166,800 -183,200	-52%	-$1.65M	0.02%	435
2013 Q4	$3.33M	Buy	+350,000	New	+$2.73M	0.04%	346

Other funds holding TLOG

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

FWC

First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Pine River Capital Management's TLOG Position: Q4 2014 in Review

Pine River Capital Management sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q4 2014, closing a stake of 209,900 shares — an estimated $873K sold.

Pine River Capital Management first reported a position in TLOG in Q4 2013 and held it in 4 quarters. The position peaked at $3.33M in Q4 2013. 31 funds tracked by Wall St. Rank hold TLOG as of Q4 2014.

Pine River Capital Management reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q4 2014 after selling out during the quarter.
Pine River Capital Management sold 209,900 TetraLogic Pharmaceuticals Corporation shares in Q4 2014, an estimated $873K.
Pine River Capital Management first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2013 and held it in 4 quarters.
Pine River Capital Management's TetraLogic Pharmaceuticals Corporation position peaked at $3.33M in Q4 2013.
31 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q4 2014.

Based on Pine River Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.